Abstract
Globally, the COVID-19 pandemic has had extreme consequences for the healthcare system and calls for diagnostic tools to monitor and understand the transmission, pathogenesis and epidemiology, as well as to evaluate future vaccination strategies. Here we have developed novel flexible ELISA-based assays for specific detection of SARS-CoV-2 antibodies against the receptor-binding domain (RBD): An antigen sandwich-ELISA relevant for large population screening and three isotype-specific assays for in-depth diagnostics. Their performance was evaluated in a cohort of 350 convalescent participants with previous COVID-19 infection, ranging from asymptomatic to critical cases. We mapped the antibody responses to different areas on protein N and S and showed that the IgM, A and G antibody responses against RBD are significantly correlated to the disease severity. These assays—and the data generated from them—are highly relevant for diagnostics and prognostics and contribute to the understanding of long-term COVID-19 immunity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was financially supported by the Carlsberg Foundation (CF20-0045) and the Novo Nordisk Foundation (205A0063505).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures involving the handling of human samples are in accordance with the principles described in the Declaration of Helsinki and ethically approved by the Regional Ethical Committee of the Capital Region of Denmark (H-20028627).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The article consists solely of original data and we have all raw files to prove it.
List of abbreviations
- ACE2
- Angiotensin-converting enzyme 2 receptor
- A.U.
- Arbitrary units
- CoV
- Coronavirus
- COVID-19
- Coronavirus Disease 2019
- CV
- Coefficient of variation
- Ig
- Immunoglobulin
- MERS
- Middle East respiratory syndrome
- OD
- Optical density
- ON
- Overnight
- Protein N
- Nucleocapsid protein
- Protein S
- Spike protein
- RBD
- Receptor binding domain
- rHSA
- Recombinant human serum albumin
- ROC
- Receiver operating characteristic
- RT
- Room temperature
- S/N
- Signal to noise
- SARS
- Severe acute respiratory syndrome
- S-ELISA
- Sandwich ELISA
